A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)
PERSEVERANCE EU
Phase 1 other active
Quick answer
A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU) for Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory is a Phase 1 program (other) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CERO THERAPEUTICS HOLDINGS, INC.
- Indication
- Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory
- Phase
- Phase 1
- Modality
- other
- Status
- active